EXAGEN INC. (XGN): Price and Financial Metrics
XGN Stock Summary
- Exagen Inc's stock had its IPO on September 19, 2019, making it an older stock than just 1.65% of US equities in our set.
- Of note is the ratio of Exagen Inc's sales and general administrative expense to its total operating expenses; 76% of US stocks have a lower such ratio.
- In terms of twelve month growth in earnings before interest and taxes, Exagen Inc is reporting a growth rate of 66.64%; that's higher than 83.37% of US stocks.
- Stocks that are quantitatively similar to XGN, based on their financial statements, market capitalization, and price volatility, are SREV, BCPC, EVER, BOXL, and ADMS.
- Visit XGN's SEC page to see the company's official filings. To visit the company's web site, go to avisetest.com.
XGN Stock Price Chart Interactive Chart >
XGN Price/Volume Stats
|Current price||$16.16||52-week high||$24.67|
|Prev. close||$16.41||52-week low||$10.29|
|Day high||$17.40||Avg. volume||62,652|
|50-day MA||$18.50||Dividend yield||N/A|
|200-day MA||$15.04||Market Cap||204.75M|
EXAGEN INC. (XGN) Company Bio
Exagen, Inc. is a commercial-stage diagnostics company. It engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company operates under the Avise brand.
XGN Latest News Stream
|Loading, please wait...|
XGN Latest Social Stream
View Full XGN Social Stream
Latest XGN News From Around the Web
Below are the latest news stories about Exagen Inc that investors may wish to consider to help them evaluate XGN as an investment opportunity.
The big shareholder groups in Exagen Inc. ( NASDAQ:XGN ) have power over the company. Insiders often own a large chunk...
Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases
SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that it will collaborate with Emory University on a new study about the long-term effects of COVID-19 infection in the development of autoimmune diseases. Emory is widely acknowledged as a leading research institution in the study of various autoimmune diseases, including lupus. The longitudinal study will further evaluate the emergence of biomarkers that are known indicators for the development of lupus, rheumatoid arthritis and other autoimmune diseases. This effort will assess the emergence of these biomarkers in mild/moderate COVID patients, among several critical patient groups, includi...
Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten public offering of 4,255,000 shares of its common stock, including 555,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $16.25 per share. The gross proceeds to Exagen from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $69.1 million. Exagen intends to use the net proceeds from the proposed offering for the development of Multi-omics capabilities, including build out of its clinical laboratory, advancement of its product pipeline, incl...
Exagen (XGN) has priced its public offering of 3.7M common shares at $16.25/share, for expected gross proceeds of $60.1M.Underwriters' over-allotment is an additional 555K shares. Net proceeds will be used for build out of clinical laboratory, advancement of its product pipeline, for working capital and other general corporate purposes.Closing date...
XGN Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!